查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1268946

2023-2030 年全球精準醫學軟件市場

Global Precision Medicine Software Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

精準醫學軟件市場預計到 2030 年將達到 37.064 億美元，高於 2022 年創紀錄的 15.507 億美元，預測期內復合年增長率為 11.8%。 主要市場參與者通過產品發布、收購、合作、聯合研究和業務擴展等各種市場策略佔據了大部分市場份額。

例如，2023 年 3 月 1 日，飛利浦將連接其腫瘤學、病理學、放射學和心髒病學團隊，創建一個完整的醫療平台，以提高臨床信心並提高診斷和治療的準確性。推出可互操作的智能成像系統和信息學解決方案。 例如，2023 年 1 月 9 日，癌症分子分析領域的領導者 Foundation Medical, Inc. 和無細胞 DNA 檢測領域的全球領導者 Natera, Inc. 宣布他們將加入早期訪問計劃因此，設計了 FoundationOne Tracker，一種個性化的循環腫瘤 DNA (ctDNA) 監測分析。 此外，臨床試驗現在可以採用試驗性藥物試驗變體。

近年來，受基因組學進步、電子健康記錄 (EHR) 日益普及以及個性化醫療需求不斷增長的推動，全球精準醫學軟件市場經歷了顯著增長。 隨著精準醫學成為主流並融入常規臨床實踐，預計未來幾年市場將繼續以顯著速度增長。

基因組學的快速發展（例如 DNA 測序技術）產生了大量的基因組數據。 精準醫學軟件在分析和解釋這些基因組數據以識別緻病基因突變、指導治療和製定個性化治療計劃方面發揮著關鍵作用。

市場動態

電子健康檔案（EHR）實施進展

電子健康記錄 (EHR) 的激增是醫療保健行業（包括精準醫療行業）的主要推動力。 EHR 是患者病史的數字化版本，包括醫療狀況、診斷、治療、用藥和其他相關健康信息，以電子形式存儲並可供授權的醫療保健專業人員訪問。

EHR 的採用受到多種因素的推動，包括政府舉措、監管要求、技術進步以及改善醫療保健結果的需要。 EHR 使醫療保健提供者能夠快速輕鬆地訪問患者的綜合病史，包括對精準醫療至關重要的基因組數據。 這使醫療保健提供者能夠就患者護理做出更明智的決定，制定個性化的治療計劃，並根據個人健康特徵進行有針對性的干預。。

EHR 可以在不同的醫療保健提供者和設施之間無縫交換患者信息，促進更好的護理協調。 這在精準醫學中尤為重要，因為患者護理可能涉及多個利益相關者，包括遺傳學家、腫瘤學家、藥劑師和其他專家。 EHR 可以交換基因組數據、臨床數據和其他相關信息，以支持不同醫療機構的精準醫療決策。

精準醫療軟件成本高

精準醫療軟件的高成本是影響全球精準醫療軟件市場增長的重要市場製約因素之一。 精準醫學軟件涉及復雜的算法和數據分析，以分析和解釋大量數據，包括基因組、臨床和生活方式數據，並為患者提供個性化的治療計劃。 此類高級軟件解決方案的應用程序類型、實施和維護可能成本高昂，對部署和利用提出了挑戰。

精密醫學軟件需要持續研究，以跟上基因組數據分析、數據集成和決策算法的最新進展。 投資研發以開發和更新精準醫學軟件可能成本高昂，尤其是對於資源有限的小型企業和組織而言。

COVID-19 影響分析

COVID-19 疫情正在加速數字技術在醫療保健領域的採用，包括遠程醫療、遠程監控和數字健康解決方案的使用。 這種對數字技術的日益依賴也可能推動精準醫學軟件的採用，該軟件能夠遠程訪問基因組數據、遠程醫療護理、遠程監控和為患者制定個性化治療計劃。 精準醫學軟件還可以幫助管理針對 COVID-19 的潛在治療方法和疫苗的臨床試驗。

COVID-19 大流行擾亂了許多領域的研究，包括精準醫學。 臨床試驗、數據收集和研究合作受到封鎖、旅行限制和資源重新分配以應對大流行病的影響。

俄烏衝突分析

精準醫學在很大程度上依賴於大量多樣的數據集的可用性，以進行分析和決策。 衝突可能會擾亂俄羅斯和烏克蘭之間的數據共享和交換，導致精準醫學研究和應用對相關患者數據的訪問受到限制。 衝突可能導致醫療保健專業人員（包括研究人員和臨床醫生）從受影響地區搬遷。 因此，研究工作可能會因精準醫學領域專業知識和人才的流失而受挫。 需要注意的是，形勢複雜多變，對精準醫療軟件的實際影響可能因衝突的具體情況而異。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按投放模式分類的摘要
  • 按應用類型分類的片段
  • 最終用戶的片段
  • 區域摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 電子健康記錄 (EHR) 越來越受歡迎
      • 對個性化醫療的需求不斷增長
    • 約束因素
      • 研發費用
      • 數據存儲和計算成本
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章分銷模式

  • 基於雲的交付模式
  • 本地交付模式

第 8 章按應用程序類型

  • 腫瘤科
  • 藥物基因組學
  • 罕見病
  • 其他

第 9 章最終用戶

  • 醫務人員
  • 研究中心/學術機構
  • 製藥和生物技術公司
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 競爭場景
  • 市場分析/份額分析
  • 併購分析

第12章公司簡介

  • Foundation Medicine Inc.（F. Hoffmann-La Roche Ltd）
    • 公司簡介
    • 交付模式組合和評論
    • 財務摘要
    • 主要應用類型
  • Koninklijke Philips N.V.
  • QIAGEN
  • Hitachi Vantara LLC（Hitachi）
  • Sophia Genetics SA
  • Pieriandx, Inc.（Velsera）
  • Syapse, Inc
  • MediCardia Health
  • Lifeomic Holdings LLC
  • Fabric Genomics, Inc.

第13章 附錄

簡介目錄
Product Code: HCIT1725

Market Overview

The precision medicine software market is expected to reach US$ 3,706.4 million in 2030, from its recorded value of US$ 1,550.7 million in 2022, growing with a CAGR of 11.8% during the forecast period. A few of the key market players such as Hitachi Vantara LLC (Hitachi, Ltd.), Koninklijke Philips N.V., Syapse, Inc., SOPHiA GENETICS, QIAGEN, Velsera, Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd), 2bPrecise (AccessDx Laboratory), Pieriandx, Inc., MediCardia Health, Translational Software Inc., and Lifeomic Holdings LLC among others hold a majority of the market share through various market strategies such as product launches, acquisitions, partnerships, collaborations, and business expansions.

For instance, on March 01, 2023, Philips introduced its completely interoperable smart imaging systems and informatics solutions to connect crews in oncology, pathology, radiology, and cardiology to improve clinical conviction and promote precision in diagnosis and treatment. For instance, on January 09, 2023, the personalized circulating tumor DNA (ctDNA) monitoring assay FoundationOne Tracker was invented by Foundation Medical, Inc., a leader in molecular profiling for cancer, and Natera, Inc., a world leader in cell-free DNA testing, as part of an early access program for clinical usage. Moreover, clinical trials can now employ the test's investigational use-only variant.

The global precision medicine software market has been witnessing significant growth in recent years, driven by advancements in genomics, increasing adoption of electronic health records (EHRs), and growing demand for personalized medicine. The market is expected to continue to grow at a considerable rate in the coming years, as precision medicine becomes more mainstream and integrated into routine clinical practice.

Rapid advancements in genomics, including DNA sequencing technologies, have enabled the generation of vast amounts of genomic data. Precision medicine software plays a critical role in analyzing and interpreting this genomic data to identify disease-causing genetic mutations, guide treatment decisions, and develop personalized treatment plans.

Market Dynamics

Increasing adoption of electronic health records (EHRs)

The increasing adoption of electronic health records (EHRs) has been a significant driver in the healthcare industry, including the field of precision medicine. EHRs are digital versions of a patient's medical history, including their medical conditions, diagnoses, treatments, medications, and other relevant health information, which are stored in electronic format and can be accessed by authorized healthcare providers.

The adoption of EHRs has been driven by various factors, including government initiatives, regulatory requirements, technological advancements, and the need for improved healthcare outcomes. EHRs provide healthcare providers with quick and easy access to a patient's comprehensive medical history, including genomic data, which is crucial for precision medicine. This enables healthcare providers to make more informed decisions about patient care, develop personalized treatment plans, and tailor interventions based on an individual's unique health characteristics.

EHRs allow for a seamless exchange of patient information among different healthcare providers and facilities, facilitating better coordination of care. This is especially important in precision medicine, where multiple stakeholders, including geneticists, oncologists, pharmacists, and other specialists, may be involved in a patient's care. EHRs enable the exchange of genomic data, clinical data, and other relevant information, supporting precision medicine decision-making across different healthcare settings.

High cost of precision medicine software

The high cost of precision medicine software is one of the significant market restraints that may impact the global precision medicine software market growth. Precision medicine software involves complex algorithms and data analytics to analyze and interpret large amounts of data, including genomic data, clinical data, and lifestyle data, to provide personalized treatment plans for patients. The application type, implementation, and maintenance of such sophisticated software solutions can be costly, which may pose challenges for adoption and utilization.

Precision medicine software requires continuous research to keep up with the latest advancements in genomic data analysis, data integration, and decision-making algorithms. Investing in R&D to develop and update precision medicine software can be costly, especially for smaller companies or organizations with limited resources.

COVID-19 Impact Analysis

The COVID-19 pandemic has accelerated the adoption of digital technologies in healthcare, including the use of telemedicine, remote monitoring, and digital health solutions. This increased reliance on digital health technologies may also drive the adoption of precision medicine software, which can provide remote access to genomic data, facilitate teleconsultations, and enable remote monitoring and personalized treatment plans for patients. Precision medicine software can also aid in the management of clinical trials for potential treatments and vaccines for COVID-19.

The COVID-19 pandemic has disrupted research in many areas, including precision medicine. Clinical trials, data collection, and research collaborations have been impacted by lockdowns, travel restrictions, and resource reallocation to address the pandemic.

Russia-Ukraine Conflict Analysis

Precision medicine relies heavily on the availability of large and diverse datasets for analysis and decision-making. The conflict may disrupt data sharing and exchange between Russia and Ukraine, leading to limited access to relevant patient data for precision medicine research and applications. Conflict can lead to the displacement of healthcare professionals, including researchers and clinicians, from the affected region. This can result in a loss of expertise and talent in the field of precision medicine, leading to potential setbacks in research efforts. It's important to note that the situation is complex and evolving, and the actual impact on precision medicine software may vary depending on the specific circumstances of the conflict.

Segment Analysis

The global precision medicine software market is segmented based on delivery mode, application type, end user, and region.

Cloud-based segment drives the market growth

The market value for cloud-based segment is likely to reach US$ 2,436.6 million in 2030, from its recorded value of US$ 1,011.8 million in 2022, growing with a CAGR of 11.9% during the forecast period (2023 to 2030).

Cloud-based deployment means renting an internet space from a third party and storing the data on remote servers. This solution is convenient as it has no upfront costs and requires no additional staff to maintain hardware. Cloud deployment is scalable and flexible according to the budget and usage, eases the burden on IT staff, and easier to perform regular backups.

For instance, Synapse Raydar is a complete real-world data platform created by combining technology, deep clinical understanding, regulatory experience, and rigorous quality control. Raydar converts clinically complicated, highly contextual oncology data into actionable insights.

Raydar's patented capabilities illuminate the entire patient journey via Raydar Interoperability, Raydar Knowledge Management Services, Raydar AI, and Raydar Algo. Similarly, 2bPrecise technology, which is cloud-based, absorbs molecular data from laboratories and clinical information from EHRs, synthesizing them into a clinical-genomic ontology and giving precision medicine insights to doctors inside their familiar workflow across any EHR. Furthermore, the solution is designed to interact with changing information sources and care recommendations. When combined with the rest of the patient information, this actionable data set contributes to improved diagnosis and early treatment.

Geographical Analysis

The strong presence of major players and increased awareness about the use of eco-friendly delivery modes

The North American precision medicine software market was valued at US$ 667.2 million in 2022 and is likely to reach US$ 1,611.3 million by 2030, growing at a CAGR of 12.0% during 2023-2030.

North America accounted for the highest market share of 43.0% in 2022, which will increase to 43.37% in 2030. The presence of a large number of pharmaceutical companies, growing R&D expenditure, rising patient preference for precision medicine, collaborative agreements among manufacturers, and surging cancer patients, new product launches, and technological advancements are driving the growth of the market in the region.

For instance, according to National Cancer Institute, approximately 1,806,590 new cases were analyzed with cancer, which led to 606,520 deaths in 2020. Moreover, the American Cancer Society identified 1.9 million cancer cases in 2021, and over 608,570 deaths were cancer-related. Similarly, CDC assessed that annual new cancer cases will be 29.5 million by 2040.

Moreover, the presence of key market players such as Syapse, Inc, 2bprecise, LLC, Fabric Genomics, Inc., Foundation Medicine, Inc., Velsera, Translational Software Inc., LifeOmic Holdings LLC, and Koninklijke Philips N.V. among others holding most of the precision medicine software market is expected to ensure the growth of North American precision medicine software market at a high CAGR throughout the forecast period.

Competitive Landscape

The precision medicine software market is highly competitive with the presence of a large number of existing major players and small vendors. Some of the major players in the global precision medicine software market include Hitachi Vantara LLC (Hitachi, Ltd.), Koninklijke Philips N.V., Syapse, Inc., SOPHiA GENETICS, QIAGEN, Velsera, Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd), 2bPrecise (AccessDx Laboratory), Pieriandx, Inc., MediCardia Health, Translational Software Inc., and Lifeomic Holdings LLC among others.

Why Purchase the Report?

  • To visualize the global precision medicine software market segmentation based on delivery mode, application type, end user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-Application Type.
  • Excel data sheet with numerous data points of precision medicine software market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Delivery Mode mapping available as Excel consisting of key Delivery Modes of all the major players.

The global precision medicine software market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Delivery Mode
  • 3.2. Snippet by Application Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Electronic Health Records (EHRs)
      • 4.1.1.2. Growing Demand for Personalized Medicine
    • 4.1.2. Restraints
      • 4.1.2.1. Research and Development (R&D) Costs
      • 4.1.2.2. Data Storage and Computing Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Delivery Mode

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 7.1.2. Market Attractiveness Index, By Delivery Mode
  • 7.2. Cloud-Based Delivery Mode*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. On-Premise Delivery Mode

8. By Application Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 8.1.2. Market Attractiveness Index, By Application Type
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Pharmacogenomics
    • 8.2.4. Rare Diseases
    • 8.2.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Health Care Providers*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Research Centers and Academic Institutes
    • 9.2.4. Pharmaceutical & Biotechnology Companies
    • 9.2.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd) *
    • 12.1.1. Company Overview
    • 12.1.2. Delivery Mode Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Application Types
  • 12.2. Koninklijke Philips N.V.
  • 12.3. QIAGEN
  • 12.4. Hitachi Vantara LLC (Hitachi)
  • 12.5. Sophia Genetics SA
  • 12.6. Pieriandx, Inc. (Velsera)
  • 12.7. Syapse, Inc
  • 12.8. MediCardia Health
  • 12.9. Lifeomic Holdings LLC
  • 12.10. Fabric Genomics, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us